Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality

Charity I Oyedeji, MD, Carl Pieper, PhD, Katherine Hall, PhD, Miriam Morey, PhD, Heather Whitson, MD MHS, John J. Strouse, MD, PhD

Blood (2019) 134 (Supplement_1): 518.

https://doi.org/10.1182/blood-2019-122634

Published: 2019

Journal Articles

Tumor Lysis Syndrome Management in Community Oncology Settings

Scott Howard, MD

Blood (2019) 134 (Supplement_1): 5875.

https://doi.org/10.1182/blood-2019-132266

Published: 2019

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Comorbid Conditions in Newly Diagnosed Patients with Acute Promyelocytic Leukemia (APL) in "Real World" Patients; Decreased Induction Mortality Despite a High Comorbid Index

Stephanie Debragga, Kathryn Sarah Simon, PA-C, Prachi Kharkhanis, Sheldon Bolds, Catherine R. Caprara, MSN, NP, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 3379.

https://doi.org/10.1182/blood.V130.Suppl_1.3379.3379

Published: 2017

Journal Articles

Assessment of Referral Patterns of Adult Patients to a Sickle Cell Disease Specialty Clinic within a Statewide Sickle Cell Network

Earleisha Felder, PA-C, Gary Link, Julie Kanter, MD

Blood (2017) 130 (Supplement 1): 3358.

https://doi.org/10.1182/blood.V130.Suppl_1.3358.3358

Published: 2017

Journal Articles

A Normal Prothrombin Time, Activated Partial Thromboplastin Time and Fibrinogen Level Do Not Eliminate Disseminated Intravascular Coagulation (DIC) and Bleeding Risk in Patients with Acute Promyelocytic Leukemia

Kathryn Sarah Simon, PA-C, Prachi Kharkhanis, Catherine R. Caprara, MSN, NP, Stephanie Debragga, Sheldon Bolds, Saleh Alghsoon, Martha L. Arellano, MD, Ravindra Kolhe, MD PhD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 4869.

https://doi.org/10.1182/blood.V130.Suppl_1.4869.4869

Published: 2017

Journal Articles

Acute Promyelocytic Leukemia (APL) Induction Therapy and Incidence of Renal Insufficiency

Prachi Kharkhanis, Sheldon Bolds, Stephanie Debragga, Catherine R. Caprara, MSN, NP, Kathryn Sarah Simon, PA-C, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5020.

https://doi.org/10.1182/blood.V130.Suppl_1.5020.5020

Published: 2017

Journal Articles

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

Catherine R. Caprara, MSN, NP, Prachi Kharkhanis, Kathryn Sarah Simon, PA-C, Stephanie Debragga, Sheldon Bolds, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5071.

https://doi.org/10.1182/blood.V130.Suppl_1.5071.5071

Published: 2017

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

Journal Articles

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 1622.

https://doi.org/10.1182/blood.V128.22.1622.1622

Published: 2016

Journal Articles

Darbepoetin Hits a Double As Epoetin Hits a Home Run in Response to the 2007 FDA Black Box Warning

Virginia Noxon, Charles L. Bennett, MD PhD

Blood (2015) 126 (23): 2075.

https://doi.org/10.1182/blood.V126.23.2075.2075

Published: 2015

Journal Articles

Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Anand Jillella, MD, Martha Arellano, MD, Asad Bashey, MD PhD, Sarah I. Vidito, DO, Robert K. Stuart, MD, Caleb Leung, Kaitlin Sitchenko, Manila Gaddh, MD, Leonard T Heffner, Jr., MD, Ravindra B. Kolhe, MD PhD, Jacques Galipeau, MD, Amelia Langston, MD, Vamsi K Kota, MD

Blood (2015) 126 (23): 3779.

https://doi.org/10.1182/blood.V126.23.3779.3779

Published: 2015

Journal Articles

Evaluating Causes of Back Pain in Patients with Sickle Cell Disease

Andrea R Whitfield, DO, Julie Kanter, MD

Blood (2015) 126 (23): 4593.

https://doi.org/10.1182/blood.V126.23.4593.4593

Published: 2015

Journal Articles

Novel Epigenetic Modulators That Promote Fetal Hemoglobin Production for the Prevention of Sickle Cell Disease Related Complications

Rebecca M. Cafiero, MD, Steven Holshouser, Craig Kutz, Julie Kanter, MD, Patrick Woster, PhD

Blood (2015) 126 (23): 973.

https://doi.org/10.1182/blood.V126.23.973.973

Published: 2015

Journal Articles

Pediatric Hemophagocytic Lymphohistocytosis (HLH): A Single Institution Experience in the Diagnosis and Management of This Variable Disease

Hawazen S. Alsaedi, MD, Michael Stump, MD, Wenzinger Christopher, MD, Lazarchick John, MD, Jennifer Jaroscak, MD

Blood (2014) 124 (21): 4982.

https://doi.org/10.1182/blood.V124.21.4982.4982

Published: 2014

Journal Articles

Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center

Caroline Dupre Vaughn, RN, Joseph Mazur, PharmD, Joyce Foster, MHS,MT(ASCP), John Lazarchick, MD, Alice Boylan, MD, Charles S Greenberg, MD

Blood (2014) 124 (21): 4848.

https://doi.org/10.1182/blood.V124.21.4848.4848

Published: 2014

Journal Articles

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Virginia Noxon, Charles L Bennett, MD PhD MPP, Jun Wu

Blood (2014) 124 (21): 1276.

https://doi.org/10.1182/blood.V124.21.1276.1276

Published: 2014

Journal Articles

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

Anand P. Jillella, MD, Ravindra B. Kolhe, MD, PhD, Farrukh Awan, MD, MS, Kavita Natrajan, MBBS, Vamsi Kota, M.B;B.S

Blood (2013) 122 (21): 5597.

https://doi.org/10.1182/blood.V122.21.5597.5597

Published: 2013

Journal Articles

Outpatient Visits, Hospitalizations and Emergency Department Visits Among Patients with Sickle Cell Disease On Medicaid: Trends in 14 USA States, 2006–2007.

Benjamin Ansa, MD, Tom Adamkiewicz, MD, MSCR, FRCP(C), Yvonne Fry-Johnson, MD, MSCR, Gregory Strayhorn, MD, PhD, Barbara Moore, George S Rust, MD, MPH

Blood (2012) 120 (21): 3181.

https://doi.org/10.1182/blood.V120.21.3181.3181

Published: 2012

Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 3959.

https://doi.org/10.1182/blood.V118.21.3959.3959

Published: 2011

NARROW

Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality

Tumor Lysis Syndrome Management in Community Oncology Settings

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Comorbid Conditions in Newly Diagnosed Patients with Acute Promyelocytic Leukemia (APL) in "Real World" Patients; Decreased Induction Mortality Despite a High Comorbid Index

Assessment of Referral Patterns of Adult Patients to a Sickle Cell Disease Specialty Clinic within a Statewide Sickle Cell Network

A Normal Prothrombin Time, Activated Partial Thromboplastin Time and Fibrinogen Level Do Not Eliminate Disseminated Intravascular Coagulation (DIC) and Bleeding Risk in Patients with Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL) Induction Therapy and Incidence of Renal Insufficiency

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Darbepoetin Hits a Double As Epoetin Hits a Home Run in Response to the 2007 FDA Black Box Warning

Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Evaluating Causes of Back Pain in Patients with Sickle Cell Disease

Novel Epigenetic Modulators That Promote Fetal Hemoglobin Production for the Prevention of Sickle Cell Disease Related Complications

Pediatric Hemophagocytic Lymphohistocytosis (HLH): A Single Institution Experience in the Diagnosis and Management of This Variable Disease

Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

Outpatient Visits, Hospitalizations and Emergency Department Visits Among Patients with Sickle Cell Disease On Medicaid: Trends in 14 USA States, 2006–2007.

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only